Now Eylea Not Down Asleep: Regeneron Up for 'Dogfight'

As Wall Street mulled fourth-quarter sales numbers for Regeneron Pharmaceuticals Inc.'s macular degeneration drug Eylea (aflibercept), which beat expectations but disappointed some investors, CEO Leonard Schleifer spoke to the J.P. Morgan Healthcare Conference, outlining the future of the drug as it faces competition on two fronts.